Sector News

BioMarin snaps up Prosensa for around $840m

November 24, 2014
Life sciences
BioMarin Pharmaceuticals is acquiring Dutch group Prosensa in a deal valued at up to around $840 million.
 
The group said it will offer to buy all of Prosensa’s outstanding ordinary stock for $17.75 per share, for a total upfront consideration of around $680 million, as well as two $80-million milestones contingent on the approval of drisapersen for Duchenne Muscular Dystrophy (DMD) in the US (no later than May 15, 2016) and Europe (before February 15, 2017).
 
The move buys BioMarin access to multiple orphan-drug candidates – such as drisapersen, which has a shot at becoming first approved treatment for the rare genetic disease, albeit for about just 13% of patients (who carry a particular mutation) – leveraging the firm’s proprietary RNA-modulating technology platform for the treatment of various genotypes of DMD and other genetic disorders.      
 
The transaction is expected to be accounted for as a business combination, BioMarin said, also noting that it plans to maintain operations at Prosensa’s headquarters, based in Leiden, The Netherlands and integrate personnel from that office. 
 
“BioMarin is dedicated to the rare disease community, and the acquisition of Prosensa fits strategically with our mission of delivering therapies that address serious unmet medical needs,” said its chief Jean-Jacques Bienaimé, while Prosensa’s head said the move while help his firm’s mission by “bringing innovative therapies to patients across the world as quickly and efficiently as possible”.
 
By Selina McKee
 
Source: Pharma Times

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]